The MASH field have hailed the very first approved MASH therapeutic with Madrigal’s drug gaining FDA approval this March opening the doors to a wave of therapeutics from Eli Lilly, Boehringer Ingelheim, AstraZeneca, Amgen, Akero Therapeutics and more that hold huge promise in phase 1, 2, and 3 clinical trials.  Paired with the boom of GLP-1s in the metabolic space, these milstones have reinvigorated investment in the space.

From optimizing clinical trial design, overcoming regulatory challenges, combatting fibrosis, navigating GLP-1 usage, optimizing RWE integration and achieving accurate non-invasive biomarkers, this Summit is your onestop-shop. The 8th MASH Drug Development Summit is the venue for the community to unite and discuss the evolving drug development opportunity for MASH and metabolic diseases.  

Across 2 conference days, with Preclinical and Translational, and Clinical and Regulatory tracks, a poster session, and an additional pre-conference workshop designed for innovation scouting, strategic portfolio partnering and networking with investors. Join 120+ C-Level cardiometabolic stakeholders and thought leaders to streamline the development of the six MASH late-stage assets in phrase 3 and a plethora of assets in phase 1-2. 

Don’t miss this key opportunity to share the future of you MASH development pipeline!